adamantane has been researched along with Rheumatoid Arthritis in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.13) | 29.6817 |
| 2010's | 10 (31.25) | 24.3611 |
| 2020's | 21 (65.63) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, M; Kaneko, Y; Kato, D; Miyatake, D; Takeuchi, T; Tanaka, Y | 1 |
| Fukuda, M; Izutsu, H; Kaneko, Y; Kato, D; Rokuda, M; Takeuchi, T; Tanaka, Y | 2 |
| Emori, T; Fujii, Y; Hanaoka, K; Nakamura, Y; Nakano, M; Sugahara, S; Suzuki, T; Takahashi, J; Takeshita, N | 1 |
| Fujii, Y; Ishikawa, G; Kwon, C | 1 |
| Lee, YH; Song, GG | 2 |
| Fujii, Y; Fukahori, H; Imamura, E; Kitanaga, Y; Kubo, S; Nakahara, Y; Nakayamada, S; Tanaka, Y | 1 |
| Chen, YH; Izutsu, H; Kaneko, Y; Kawakami, A; Nakashima, Y; Rokuda, M; Shiomi, T; Song, YW; Takeuchi, T; Tanaka, S; Tanaka, Y; Ushijima, S; Yamada, E | 1 |
| Izutsu, H; Tanaka, Y | 1 |
| Gyu Song, G; Ho Lee, Y | 1 |
| Morinobu, A | 1 |
| Emori, T; Fujii, Y; Hashimoto, M; Higashi, Y; Ito, H; Kasahara, M; Narumiya, S; Sugahara, S | 1 |
| Akinlade, B; Cao, Y; Chindalore, V; Moy, S; Sawamoto, T; Valluri, U; Zhang, W; Zhu, T | 1 |
| Kambayashi, A; Kaneko, Y; Kiyota, T; Nishimura, T; Oda, K; Shibata, M; Toyoshima, J | 1 |
| Kaneko, Y | 1 |
| Almengor-Montenegro, O; Amaya-Cabrera, EL; Cerpa-Cruz, S; González-Díaz, V; Gutiérrez-Ureña, SR; Martínez-Bonilla, GE; Rosal-Arteaga, C; Uribe-Martínez, JF; Ventura-Valenzuela, ME | 1 |
| Aletaha, D; Baraliakos, X; Boehncke, WH; de Wit, M; Dörner, T; Dougados, M; Emery, P; Fleischmann, RM; Geissler, K; Isaacs, JD; Kerschbaumer, A; Kremer, J; Lee, EB; Maksymowych, WP; McInnes, I; Nash, P; Pope, JE; Smolen, JS; Stoffer-Marx, M; Takeuchi, T; Tam, LS; Tanaka, Y; Trauner, M; van den Bosch, F; van der Heijde, D; Voshaar, M; Westhovens, R; Winthrop, KL; Xavier, R | 1 |
| Chen, C; Sun, C; Zhou, Y | 1 |
| Izutsu, H; Kaibara, A; Kaneko, Y; Nishimura, T; Shibata, M; Toyoshima, J | 1 |
| Fukuda, M; Izutsu, H; Kaneko, Y; Kato, D; Rokuda, M; Schultz, NM; Takeuchi, T; Tanaka, Y | 1 |
| Amano, Y; Hamaguchi, H; Higashi, Y; Inoue, T; Ito, M; Moritomo, A; Nakai, K; Nakajima, Y; Nomura, N; Shirakami, S | 1 |
| Westhovens, R | 1 |
| Aykara, I; Diller, M; Frommer, K; Hasseli, R; Hülser, ML; Müller-Ladner, U; Neumann, E; Rehart, S | 1 |
| Feng, Q; Guo, M; Qiu, Q; Tan, X | 1 |
| Keam, SJ; Markham, A | 1 |
| Iwasaki, M; Izutsu, H; Kaneko, Y; Katayama, K; Kawakami, A; Rokuda, M; Shiomi, T; Takeuchi, T; Tanaka, S; Tanaka, Y; Ushijima, S; van der Heijde, D; Yamada, E | 1 |
| Akazawa, R; Chen, YH; Iwasaki, M; Izutsu, H; Kaneko, Y; Kawakami, A; Lee, SH; Rokuda, M; Shiomi, T; Song, YW; Takeuchi, T; Tanaka, S; Tanaka, Y; Ushijima, S; Wei, JC; Yamada, E | 1 |
| Ishikura, H; Iwasaki, M; Kaneko, Y; Saeki, S; Takeuchi, T; Tanaka, Y | 1 |
| Garg, JP; Genovese, MC; Gutierrez-Ureña, SR; Kivitz, AJ; Kristy, R; Poiley, J; Shay, K; Wang, X; Zubrzycka-Sienkiewicz, A | 1 |
| Cardiel, MH; Codding, C; Garg, JP; Genovese, MC; Greenwald, M; Kivitz, AJ; Shay, K; Wang, A; Wang, X; Zubrzycka-Sienkiewicz, A | 1 |
| Bourrié, B; Bribes, E; Casellas, P; De Nys, N; Esclangon, M; Galiègue, S; Garcia, L; Lair, P; Paul, R; Thomas, C; Vernières, JC | 1 |
10 review(s) available for adamantane and Rheumatoid Arthritis
| Article | Year |
|---|---|
A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Herpes Zoster; Humans; Niacinamide; Prednisolone | 2022 |
Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Dose-Response Relationship, Drug; Humans; Network Meta-Analysis; Niacinamide; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Humans; Network Meta-Analysis; Niacinamide; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Heterocyclic Compounds, 3-Ring; Humans; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Triazoles | 2020 |
JAK inhibitors for the treatment of rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Benzofurans; Cardiovascular Diseases; Herpes Zoster; Humans; Janus Kinases; Molecular Targeted Therapy; Neutropenia; Niacinamide; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Venous Thromboembolism | 2020 |
Efficacy and safety of peficitinib in rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Herpes Zoster; Humans; Janus Kinases; Niacinamide; Protein Kinase Inhibitors | 2020 |
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Topics: Adamantane; Advisory Committees; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Cytokines; Drug Therapy, Combination; Europe; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Niacinamide; Piperidines; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Rheumatology; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Triazoles | 2021 |
Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles; Valine | 2019 |
JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
Topics: Adamantane; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Proliferation; Humans; Janus Kinase 3; Janus Kinase Inhibitors; Methotrexate; Niacinamide; Piperidines; Pyrimidines; Pyrroles | 2019 |
Peficitinib: First Global Approval.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Approval; Humans; Janus Kinases; Niacinamide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2019 |
11 trial(s) available for adamantane and Rheumatoid Arthritis
| Article | Year |
|---|---|
Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis.
Topics: Adamantane; Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Herpes Zoster; Humans; Middle Aged; Niacinamide; Treatment Outcome; Young Adult | 2022 |
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Topics: Adamantane; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Female; Herpes Zoster; Humans; Janus Kinase Inhibitors; Japan; Male; Methotrexate; Middle Aged; Nasopharyngitis; Niacinamide; Republic of Korea; Severity of Illness Index; Taiwan; Treatment Outcome | 2020 |
Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis.
Topics: Adamantane; Adult; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Drug Interactions; Female; Half-Life; Humans; Male; Methotrexate; Middle Aged; Niacinamide | 2020 |
The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two-Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers.
Topics: Adamantane; Administration, Oral; Adult; Area Under Curve; Arthritis, Rheumatoid; Biological Availability; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Compounding; Drug Development; Fasting; Food; Healthy Volunteers; Humans; Janus Kinase Inhibitors; Japan; Male; Niacinamide; Safety; Therapeutic Equivalency; Treatment Outcome | 2021 |
A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years.
Topics: Adamantane; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Asian People; Drug Tolerance; Female; Humans; Male; Middle Aged; Niacinamide; Treatment Outcome | 2021 |
Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Humans; Methotrexate; Niacinamide; Patient Reported Outcome Measures; Physicians; Treatment Outcome | 2021 |
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Topics: Adamantane; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Substitution; Female; Herpes Zoster; Humans; Immunosuppressive Agents; Infections; Janus Kinase Inhibitors; Japan; Male; Methotrexate; Middle Aged; Niacinamide; Severity of Illness Index; Treatment Outcome | 2019 |
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Topics: Adamantane; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Double-Blind Method; Drug Substitution; Female; Herpes Zoster; Humans; Immunosuppressive Agents; Infections; Janus Kinase Inhibitors; Japan; Male; Middle Aged; Niacinamide; Severity of Illness Index; Treatment Outcome | 2019 |
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.
Topics: Adamantane; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Janus Kinases; Japan; Male; Middle Aged; Niacinamide; Severity of Illness Index; Treatment Outcome | 2016 |
Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Janus Kinases; Male; Methotrexate; Middle Aged; Niacinamide; Severity of Illness Index; Treatment Outcome | 2017 |
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
Topics: Adamantane; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxychloroquine; Janus Kinase 3; Male; Middle Aged; Niacinamide; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2017 |
11 other study(ies) available for adamantane and Rheumatoid Arthritis
| Article | Year |
|---|---|
Peficitinib improves bone fragility by recovering bone turnover imbalance in arthritic mice.
Topics: Adamantane; Animals; Arthritis, Rheumatoid; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Disease Models, Animal; Janus Kinase Inhibitors; Male; Mice, Inbred DBA; Niacinamide; Osteoblasts; Osteoporosis; RANK Ligand | 2022 |
Peficitinib inhibits fibroblast-like synoviocyte activation and angiogenic vascular endothelial tube formation via inhibitory effects on PDGF and VEGF signaling in addition to JAK.
Topics: Adamantane; Arthritis, Rheumatoid; Cells, Cultured; Fibroblasts; Human Umbilical Vein Endothelial Cells; Humans; Janus Kinases; Niacinamide; Platelet-Derived Growth Factor; Signal Transduction; Synoviocytes; Tyrosine; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2022 |
In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors.
Topics: Adamantane; Arthritis, Rheumatoid; Female; Humans; Janus Kinase Inhibitors; Lymphocyte Activation; Lymphocytes; Male; Niacinamide; Phosphorylation; Scleroderma, Systemic; STAT Transcription Factors | 2020 |
Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Niacinamide | 2020 |
Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
Topics: Adamantane; Apoptosis; Arthritis, Rheumatoid; Azetidines; Cells, Cultured; Cytokines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Phosphorylation; Piperidines; Purines; Pyrazoles; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Sulfonamides; Synoviocytes | 2020 |
Peficitinib hydrobromide to treat rheumatoid arthritis.
Topics: Adamantane; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Janus Kinases; Niacinamide; Treatment Outcome | 2020 |
The optimal dosage of pefcitinib for the treatment of active rheumatoid arthritis: A protocol for an updated network meta-analysis.
Topics: Adamantane; Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Network Meta-Analysis; Niacinamide; Research Design | 2021 |
Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Models, Biological; Niacinamide; Severity of Illness Index; Treatment Outcome; Young Adult | 2021 |
Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor.
Topics: Adamantane; Administration, Oral; Animals; Arthritis, Rheumatoid; Biological Availability; Drug Discovery; Humans; Janus Kinase Inhibitors; Mice; Niacinamide; Rats; Structure-Activity Relationship | 2018 |
Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib.
Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Cell Proliferation; Chemokine CCL2; Fibroblasts; Humans; Interleukin-6; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Synovial Membrane | 2019 |
SSR125329A, a high affinity sigma receptor ligand with potent anti-inflammatory properties.
Topics: Adamantane; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Binding, Competitive; Cell Division; Cells, Cultured; Dose-Response Relationship, Drug; Enterotoxins; Female; Graft vs Host Disease; Interleukin-10; Ligands; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred Strains; Protein Subunits; Receptors, sigma; Spleen; Steroid Isomerases; Syndrome; Tumor Necrosis Factor-alpha | 2002 |